about
Nanoparticulate carriers for the treatment of coronary restenosisPlasma microRNAs as potential noninvasive biomarkers for in-stent restenosisImpact of C-reactive protein on in-stent restenosis: a meta-analysis.Anti-inflammatory effects of arsenic trioxide eluting stents in a porcine coronary model.BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease.Need for a paradigm shift in cancer prevention and clinical oncology.Incidence of moderate to severe cognitive dysfunction in patients treated with carotid artery stenting.The role of monocyte phenotype switching in peri-procedural myocardial injury and its involvement in statin therapy.Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era?A review of the biocompatibility of implantable devices: current challenges to overcome foreign body response.Drug releasing systems in cardiovascular tissue engineering.Preclinical models of restenosis and their application in the evaluation of drug-eluting stent systems.Stents and statins: history, clinical outcomes and mechanisms.Th1, Th17, CXCL16 and homocysteine elevated after intracranial and cervical stent implantation.Viral-derived Serp-1 as an adjunctive therapy for percutaneous coronary intervention: another not ready for prime time player?Incorporation of a Ligand Peptide for Immune Inhibitory Receptor LAIR-1 on Biomaterial Surfaces Inhibits Macrophage Inflammatory Responses.In vivo evaluation of a novel dexamethasone-heparin-double-coated stent for inhibition of artery restenosis and thrombosis.
P2860
Q28220309-22B7754A-4649-41AE-9C54-7DF9AE6AE23BQ28545216-AE9D2529-271F-41DF-A823-02749183F771Q33693147-178961B9-E95F-44D9-8340-BFCF07D0027EQ36635049-FBF59A6C-AAC9-46AA-8A79-983CD243D6E5Q36728852-2C6AE87C-D9BE-4626-BC61-C071CF5EDCC0Q36974680-20E2F1F0-AABF-4987-A002-AF0CF8837C92Q37275972-7BAC9EB8-9CE9-41D6-A4A8-1EA452B75D6BQ37350270-D762C3B0-C68F-41EE-AF02-8B9A74938990Q37362731-C942AFD1-DB18-4AC8-9E5E-9657017726E3Q37404318-07ED08CB-6DE1-4AFD-9B99-DFFE9CB669A8Q37451635-70C39B00-4CE5-4F82-AFD9-30D0CE1B9241Q37676695-040DC004-A619-4D47-BAFA-1C01A86AA083Q37786646-41D90AB4-F0BC-497C-87F7-E143E3B78CB8Q39350421-E422BB47-D664-462C-9708-89C22C8CF0C4Q42645331-AA6F54DC-1FE0-41C6-8384-8606B4766CDEQ46073757-8BA18C56-4FD3-4654-BB8F-A208E1D6CA36Q50803085-2D25D2C3-811D-414A-BC1C-709E3D9C5D4D
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Coronary stenting and inflammation.
@ast
Coronary stenting and inflammation.
@en
type
label
Coronary stenting and inflammation.
@ast
Coronary stenting and inflammation.
@en
prefLabel
Coronary stenting and inflammation.
@ast
Coronary stenting and inflammation.
@en
P1476
Coronary stenting and inflammation.
@en
P2093
Achille Gaspardone
Francesco Versaci
P304
P356
10.1016/J.AMJCARD.2005.09.064
P407
P577
2005-10-05T00:00:00Z